We have read with great interest the recent article by Trifilio et al. 1 on the breakthrough in zygomycosis after the administration of voriconazole in allogeneic stem cell transplant recipients.
We report a case developing this type of complication and illustrating an additional risk factor, which is delayed immune recovery after umbilical cord blood transplantation (UCBTx). The 39-year-old female patient was diagnosed with Ph chromosome positive acute lymphoblastic leukemia in March 2005. She was treated with induction and consolidation chemotherapy, including imatinib and prophylactic cranial radiotherapy. After the completion of consolidation treatment, she was in hematological remission, but had minimal residual disease as detected by PCR for the BCR-ABL transcripts. There was no familial or unrelated donor available. She was allografted with a double UCBTx after myeloablative conditioning, including CY and TBI, in November 2006. During the aplastic phase, the patient developed symptoms of probable fungal infection and was treated with voriconazole, which was continued throughout the whole post-transplant episode. The patient achieved and maintained complete molecular remission. However, she developed grade II acute and subsequent systemic chronic GVHD requiring prolonged treatment with corticosteroids and azathioprine, which was started in February 2007. Persistent mixed chimerism ( ± 50% of each cord blood) was noted, together with a very prolonged immune reconstitution with total CD3 þ cells counts not exceeding 200/mm 3 . At 18 months after SCT, while still on voriconazole, she was admitted with fever and a rapidly progressing neurological syndrome with left hemiplegia, altered consciousness and seizures. MRI imaging showed a mass on the right frontoparietal side with compression of the midline, diffuse concentric contrast captation and central necrosis (Figure 1 ). Microbiological culture of the brain biopsy as well as cerebrospinal fluid isolated Rhizopus microsporus. Subsequently, in view of the critical clinical situation, the patient was treated with a combination of liposomal amphotericin B and posaconazole, but she rapidly deteriorated and died 2 days after the initiation of treatment. Posaconazole has been added on the basis of several reports indicating clinical activity in zygomycosis infections. 
